Q-omics provides the consensus-scored GUSBP2 profile across patient tissues and cancer cell-line models. GUSBP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, GUSBP2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, GUSBP2 RNA expression shows 19,862 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight THCA, KIRC, and KIRP as cancer lineages where GUSBP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP2 survival associations across molecular data types. GUSBP2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP2 RNA expression–survival associations across cancer types. High GUSBP2 expression shows unfavorable associations in THCA, KICH, ACC and STAD, but favorable associations in HNSC and UCS. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for GUSBP2 RNA expression.
This table summarizes GUSBP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP2 shows lower tumor expression in THCA and higher tumor expression in KIRC, HNSC, LIHC, CHOL and STAD. The KIRC box plot shows higher GUSBP2 RNA expression in tumor versus normal tissue (log2 FC = +0.474, t-test p < 0.001).
This table shows molecular features associated with GUSBP2 in patient tissues and cancer cell lines. In patient samples, GUSBP2 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
